On March 23, the National Health and Medical Commission issued the "Notice on Adjusting Indications of Anti-New Coronavirus Drug PF-07321332/Ritonavir Tablets (Paxlovid), etc." Ordinary type and adults with high risk factors for progression to severe disease", delete "Adolescents aged 12-17 years weighing more than 40 kg".
PAXLOVID is a combination drug developed by Pfizer. Nematevir is a protease inhibitor that blocks the protease activity necessary for coronavirus replication. Ritonavir, on the other hand, is used to slow down the metabolism or breakdown of nematevir, allowing it to remain active in the body for longer at higher concentrations, which together affect the reproduction of the virus.
According to Pfizer's previously published clinical trial data, compared with the placebo group, patients treated with PAXLOVID within 3 days and 5 days after symptom onset had an 89% and 88% reduction in hospitalization or mortality, respectively, and viral load The amount has been reduced by a factor of 10. In the overall 28-day study population, no deaths were reported in patients receiving the drug, compared with 10 (1.6%) deaths in patients receiving placebo.
